- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Clinigen Appoints Greg Skalicky as Chief Executive Officer | 269 | Business Wire | Clinigen, the global pharmaceutical services company dedicated to accelerating access to critical medicines worldwide, today announced the appointment of Greg Skalicky as Group Chief Executive Officer... ► Artikel lesen | |
| CLINIGEN GROUP Aktie jetzt für 0€ handeln | |||||
| 09.03. | MaaT Pharma to Present Four Abstracts at the 52nd European Bone Marrow Transplantation Annual Meeting and to Highlight Clinigen-Hosted Industry Symposium on acute GvHD Management | 653 | Business Wire | Oral presentation during Presidential Plenary Session to feature the final results of the ARES pivotal Phase 3 trial evaluating MaaT013 in acute Graft-versus-Host Disease (aGvHD) with gastrointestinal... ► Artikel lesen | |
| 12.02. | Clinigen Announces World-First Pharmaceutical Approval for Prolacta Bioscience's PreemieFort Enteral Solution, Human Milk-Based Product in Japan | 353 | PR Newswire | Clinigen obtained approval for Prolacta's "PreemieFort Enteral Solution", a human milk-based fortifier, as an approved pharmaceutical product in Japan indicated for the "Nutritional management... ► Artikel lesen |
3 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 42,850 | -0,08 % | DEUTSCHE BANK RESEARCH stuft NOVO NORDISK auf 'Hold' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Novo Nordisk auf "Hold" mit einem Kursziel von 290 dänischen Kronen belassen. Auch wenn weder die Unternehmensziele noch... ► Artikel lesen | |
| GILEAD SCIENCES | 114,42 | +0,60 % | Big Pharma sucht den nächsten Blockbuster - weshalb Zelltherapien wieder stärker in den Fokus rücken | ||
| GSK | 22,530 | +1,03 % | GSK PLC - Director/PDMR Shareholding | ||
| ASTRAZENECA | 148,30 | -0,24 % | Europas wertvollster Konzern: Eine Billion Börsenwert? Dieser Chip-Gigant könnte es schaffen | © Foto: Max Gross, wallstreetONLINE Zentralredaktion - Dall-EASML ist bereits Europas wertvollster Konzern. Nun rückt sogar die Billionen-Marke näher. Doch dafür müssen KI-Boom, Chipnachfrage und Milliardeninvestitionen... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 422,50 | +0,64 % | Vertex was sole bidder in high-premium Crinetics acquisition | ||
| VIATRIS | 15,170 | +0,03 % | Merck signs licensing deals with companies including Viatris for new HIV pill | ||
| INCYTE | 103,60 | +0,10 % | Halozyme Partners Incyte To Devolop Subcutaneous Formulations Of INCA033989 Using ENHANZE Technology | WASHINGTON (dpa-AFX) - Biopharmaceutical company Halozyme Therapeutics, Inc. (HALO) announced Monday that it has entered into a global collaboration and license agreement with Incyte Corp. (INCY)... ► Artikel lesen | |
| EDWARDS LIFESCIENCES | 73,00 | +0,41 % | Edwards Lifesciences Q2 Profit Down; Raises 2026 Sales Outlook | WASHINGTON (dpa-AFX) - Edwards Lifesciences Corp. (EW) on Thursday reported a lower profit in the second quarter, as revenues increased 14%.Net income declined to $241.9 million or $0.42 per... ► Artikel lesen | |
| IONIS PHARMACEUTICALS | 50,16 | +0,86 % | Canaccord reiterates Ionis stock rating on Tryngolza advantage | ||
| GRIFOLS | 9,618 | +0,35 % | Grifols, S.A.: Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins | One trial, SIGMA, will evaluate Grifols' intravenous immunoglobulin (Ig) GAMUNEX- -C (immune globulin injection [human], 10% caprylate chromatography purified) plus standard medical treatment in patients... ► Artikel lesen | |
| ALNYLAM PHARMACEUTICALS | 238,30 | +1,02 % | ALNYLAM PHARMACEUTICALS INC: Struktur im Stillstand | ||
| LIGAND PHARMACEUTICALS | 262,00 | 0,00 % | Ligand Pharmaceuticals: Ligand to Report Second Quarter 2026 Financial Results on August 6, 2026 | ||
| UNITED THERAPEUTICS | 469,00 | +0,90 % | Liquidia vs. United Therapeutics: Which PAH Stock Is the Better Buy Now? | ||
| PERRIGO | 8,872 | +0,02 % | Perrigo Company plc: Perrigo Reports First Quarter 2026 Financial Results From Continuing Operations | Mitigating category headwinds with market share gains through implementation of Three-S plan.
Specialty Care segment achieved net sales and segment operating... ► Artikel lesen | |
| DR REDDYS | 10,200 | 0,00 % | Dividendenbekanntmachungen (24.07.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADRIANO CARE SOCIMI SA ES0105405007 - 0,1215 EUR ALEXANDERWERK AG DE000A37FTW0 - 0,5 EUR ARROWMARK FINANCIAL CORP US8617801043 0... ► Artikel lesen |
CLINIGEN GROUP PLC gehört der Branche Pharma an.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CLINIGEN GROUP PLC finden Sie auf Wallstreet Online.